{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:36:48Z","timestamp":1794609408044,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000070","name":"U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["5R01EB025192-06"],"award-info":[{"award-number":["5R01EB025192-06"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA269787-01"],"award-info":[{"award-number":["CA269787-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["I-2123-20220031"],"award-info":[{"award-number":["I-2123-20220031"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Developing lung-targeting delivery systems is essential for treating pulmonary conditions such as genetic respiratory diseases, infections, fibrosis and cancer. We synthesized and evaluated 444 lung-targeting lipids (LuT lipids) that form lipid nanoparticles (LNPs) to efficiently deliver messenger RNA and CRISPR\u2013Cas9 genome editors to lungs with minimal side effects. Empirical analyses revealed structure\u2013activity relationships, with top-performing LuT lipids possessing a unique \u2018tripod-like\u2019 structure consisting of a quaternary amine head, three long alkyl chains as legs and a short chain as a handle. LuT lipids improved endosomal escape, cargo release and endogenous targeting via adsorption of plasma proteins. Lead 1A7B13 LNPs showed a 25.5-fold improvement in mRNA delivery and a 9.2-fold increase in CRISPR\u2013Cas9 gene-editing efficiency compared to benchmark DOTAP SORT LNPs, achieving over 90% selectivity to the lungs. 1A7B13 LNPs effectively delivered IL-10 mRNA in a therapeutic model of acute lung injury. This study reveals the relationship between lipid structure and lung-targeting activity, enriching the toolkit for lung-specific carriers.<\/jats:p>","DOI":"10.1038\/s41551-026-01615-9","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:30:53Z","timestamp":1773768653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["\u2018Tripod-like\u2019 lung-targeting (LuT) lipids for highly efficient and selective LNPs for gene delivery and editing"],"prefix":"10.1038","author":[{"given":"Zeru","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-5645","authenticated-orcid":false,"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6096-0711","authenticated-orcid":false,"given":"William","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Chieh","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis Pacheco","family":"Benitez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Dilliard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0712-659X","authenticated-orcid":false,"given":"Amogh","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhen","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0215-6095","authenticated-orcid":false,"given":"Yehui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5604-7479","authenticated-orcid":false,"given":"Yufen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-9544","authenticated-orcid":false,"given":"Shiying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5686-0315","authenticated-orcid":false,"given":"Bret M.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4107-1676","authenticated-orcid":false,"given":"Lukas","family":"Farbiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3823-1931","authenticated-orcid":false,"given":"Daniel J.","family":"Siegwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"1615_CR1","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","volume":"386","author":"ED Moreira","year":"2022","unstructured":"Moreira, E. D. et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. N. Engl. J. Med. 386, 1910\u20131921 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1615_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2107058","volume":"385","author":"MG Thompson","year":"2021","unstructured":"Thompson, M. G. et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N. Engl. J. Med. 385, 320\u2013329 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1615_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1615_CR4","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","volume":"390","author":"F Locatelli","year":"2024","unstructured":"Locatelli, F. et al. Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia. N. Engl. J. Med. 390, 1663\u20131676 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1615_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1615_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa2309149","volume":"390","author":"HJ Longhurst","year":"2024","unstructured":"Longhurst, H. J. et al. CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema. N. Engl. J. Med. 390, 432\u2013441 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1615_CR7","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","volume":"390","author":"H Frangoul","year":"2024","unstructured":"Frangoul, H. et al. Exagamglogene autotemcel for severe sickle cell disease. N. Engl. J. Med. 390, 1649\u20131662 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1615_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41578-023-00617-2","volume":"9","author":"L Xue","year":"2024","unstructured":"Xue, L. et al. Responsive biomaterials: optimizing control of cancer immunotherapy. Nat. Rev. Mater. 9, 100\u2013118 (2024).","journal-title":"Nat. Rev. Mater."},{"key":"1615_CR9","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"1615_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","volume":"20","author":"E Kon","year":"2023","unstructured":"Kon, E., Ad-El, N., Hazan-Halevy, I., Stotsky-Oterin, L. & Peer, D. Targeting cancer with mRNA\u2013lipid nanoparticles: key considerations and future prospects. Nat. Rev. Clin. Oncol. 20, 739\u2013754 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1615_CR11","doi-asserted-by":"publisher","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","volume":"121","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y., Sun, C., Wang, C., Jankovic, K. E. & Dong, Y. Lipids and lipid derivatives for RNA delivery. Chem. Rev. 121, 12181\u201312277 (2021).","journal-title":"Chem. Rev."},{"key":"1615_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","volume":"8","author":"SA Dilliard","year":"2023","unstructured":"Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282\u2013300 (2023).","journal-title":"Nat. Rev. Mater."},{"key":"1615_CR13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","volume":"40","author":"AJ Barbier","year":"2022","unstructured":"Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. & Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840\u2013854 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1615_CR14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","volume":"5","author":"MP Lokugamage","year":"2021","unstructured":"Lokugamage, M. P. et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat. Biomed. Eng. 5, 1059\u20131068 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1615_CR15","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.ymthe.2018.05.014","volume":"26","author":"E Robinson","year":"2018","unstructured":"Robinson, E. et al. Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis. Mol. Ther. 26, 2034\u20132046 (2018).","journal-title":"Mol. Ther."},{"key":"1615_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41565-023-01548-3","volume":"19","author":"AY Jiang","year":"2024","unstructured":"Jiang, A. Y. et al. Combinatorial development of nebulized mRNA delivery formulations for the lungs. Nat. Nanotechnol. 19, 364\u2013375 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"1615_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120966","volume":"275","author":"JC Kaczmarek","year":"2021","unstructured":"Kaczmarek, J. C. et al. Systemic delivery of mRNA and DNA to the lung using polymer-lipid nanoparticles. Biomaterials 275, 120966 (2021).","journal-title":"Biomaterials"},{"key":"1615_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42948-2","volume":"14","author":"T Wei","year":"2023","unstructured":"Wei, T. et al. Lung SORT LNPs enable precise homology-directed repair mediated CRISPR\/Cas genome correction in cystic fibrosis models. Nat. Commun. 14, 7322 (2023).","journal-title":"Nat. Commun."},{"key":"1615_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45422-9","volume":"15","author":"L Xue","year":"2024","unstructured":"Xue, L. et al. High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models. Nat. Commun. 15, 1884 (2024).","journal-title":"Nat. Commun."},{"key":"1615_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"1615_CR21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109256118","volume":"118","author":"SA Dilliard","year":"2021","unstructured":"Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1615_CR22","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1073\/pnas.1520756113","volume":"113","author":"K Zhou","year":"2016","unstructured":"Zhou, K. et al. Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model. Proc. Natl Acad. Sci. USA 113, 520\u2013525 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1615_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat. Protoc. 18, 265\u2013291 (2023).","journal-title":"Nat. Protoc."},{"key":"1615_CR24","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"1615_CR25","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","volume":"26","author":"S Sabnis","year":"2018","unstructured":"Sabnis, S. et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26, 1509\u20131519 (2018).","journal-title":"Mol. Ther."},{"key":"1615_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11\u201321 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1615_CR27","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nri3739","volume":"14","author":"MJ Holtzman","year":"2014","unstructured":"Holtzman, M. J., Byers, D. E., Alexander-Brett, J. & Wang, X. The role of airway epithelial cells and innate immune cells in chronic respiratory disease. Nat. Rev. Immunol. 14, 686\u2013698 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"1615_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","volume":"578","author":"JA Doudna","year":"2020","unstructured":"Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229\u2013236 (2020).","journal-title":"Nature"},{"key":"1615_CR29","doi-asserted-by":"publisher","first-page":"9874","DOI":"10.1021\/acs.chemrev.6b00799","volume":"117","author":"H-X Wang","year":"2017","unstructured":"Wang, H.-X. et al. CRISPR\/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. Chem. Rev. 117, 9874\u20139906 (2017).","journal-title":"Chem. Rev."},{"key":"1615_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41568-022-00441-w","volume":"22","author":"A Katti","year":"2022","unstructured":"Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E. & Dow, L. E. CRISPR in cancer biology and therapy. Nat. Rev. Cancer 22, 259\u2013279 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"1615_CR31","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jconrel.2023.07.058","volume":"361","author":"SA Dilliard","year":"2023","unstructured":"Dilliard, S. A. et al. The interplay of quaternary ammonium lipid structure and protein corona on lung-specific mRNA delivery by selective organ targeting (SORT) nanoparticles. J. Control. Rel. 361, 361\u2013372 (2023).","journal-title":"J. Control. Rel."},{"key":"1615_CR32","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nchembio.1064","volume":"8","author":"M Schlame","year":"2012","unstructured":"Schlame, M. et al. The physical state of lipid substrates provides transacylation specificity for tafazzin. Nat. Chem. Biol. 8, 862\u2013869 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"1615_CR33","doi-asserted-by":"publisher","first-page":"e2307800120","DOI":"10.1073\/pnas.2307800120","volume":"121","author":"S Chatterjee","year":"2024","unstructured":"Chatterjee, S., Kon, E., Sharma, P. & Peer, D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc. Natl Acad. Sci. USA 121, e2307800120 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1615_CR34","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/sj.gt.3301506","volume":"8","author":"I Hafez","year":"2001","unstructured":"Hafez, I., Maurer, N. & Cullis, P. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 8, 1188\u20131196 (2001).","journal-title":"Gene Ther."},{"key":"1615_CR35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nbt.1602","volume":"28","author":"SC Semple","year":"2010","unstructured":"Semple, S. C. et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172\u2013176 (2010).","journal-title":"Nat. Biotechnol."},{"key":"1615_CR36","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41563-020-00886-0","volume":"20","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR\u2013Cas gene editing. Nat. Mater. 20, 701\u2013710 (2021).","journal-title":"Nat. Mater."},{"key":"1615_CR37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116271119","volume":"119","author":"M Qiu","year":"2022","unstructured":"Qiu, M. et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc. Natl Acad. Sci. USA 119, e2116271119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1615_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jconrel.2013.11.006","volume":"174","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. The development of an in vitro assay to screen lipid based nanoparticles for siRNA delivery. J. Control. Rel. 174, 7\u201314 (2014).","journal-title":"J. Control. Rel."},{"key":"1615_CR39","doi-asserted-by":"publisher","first-page":"5575","DOI":"10.1039\/c2cc31710a","volume":"48","author":"CL Walsh","year":"2012","unstructured":"Walsh, C. L., Nguyen, J. & Szoka, F. C. Synthesis and characterization of novel zwitterionic lipids with pH-responsive biophysical properties. Chem. Commun. 48, 5575 (2012).","journal-title":"Chem. Commun."},{"key":"1615_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39768-9","volume":"14","author":"K Liu","year":"2023","unstructured":"Liu, K. et al. Multiomics analysis of naturally efficacious lipid nanoparticle coronas reveals high-density lipoprotein is necessary for their function. Nat. Commun. 14, 4007 (2023).","journal-title":"Nat. Commun."},{"key":"1615_CR41","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1039\/D1NR08101B","volume":"14","author":"K Liu","year":"2022","unstructured":"Liu, K., Salvati, A. & Sabirsh, A. Physiology, pathology and the biomolecular corona: the confounding factors in nanomedicine design. Nanoscale 14, 2136\u20132154 (2022).","journal-title":"Nanoscale"},{"key":"1615_CR42","doi-asserted-by":"publisher","first-page":"2312026","DOI":"10.1002\/adma.202312026","volume":"36","author":"S Omo-Lamai","year":"2024","unstructured":"Omo-Lamai, S. et al. Physicochemical targeting of lipid nanoparticles to the lungs induces clotting: mechanisms and solutions. Adv. Mater. 36, 2312026 (2024).","journal-title":"Adv. Mater."},{"key":"1615_CR43","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature13589","volume":"514","author":"W Xue","year":"2014","unstructured":"Xue, W. et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514, 380\u2013384 (2014).","journal-title":"Nature"},{"key":"1615_CR44","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0140-6736(21)00439-6","volume":"398","author":"NJ Meyer","year":"2021","unstructured":"Meyer, N. J., Gattinoni, L. & Calfee, C. S. Acute respiratory distress syndrome. Lancet 398, 622\u2013637 (2021).","journal-title":"Lancet"},{"key":"1615_CR45","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1126\/science.adk9428","volume":"384","author":"Y Sun","year":"2024","unstructured":"Sun, Y. et al. In vivo editing of lung stem cells for durable gene correction in mice. Science 384, 1196\u20131202 (2024).","journal-title":"Science"},{"key":"1615_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/1547691X.2018.1460425","volume":"15","author":"AJ Nelson","year":"2018","unstructured":"Nelson, A. J. et al. Sex differences impact the lung-bone inflammatory response to repetitive inhalant lipopolysaccharide exposures in mice. J. Immunotoxicol. 15, 73\u201381 (2018).","journal-title":"J. Immunotoxicol."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01615-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01615-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01615-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:02:09Z","timestamp":1783706529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01615-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":46,"alternative-id":["1615"],"URL":"https:\/\/doi.org\/10.1038\/s41551-026-01615-9","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A provisional patent application covering compounds and compositions for targeting lung has been filed by UTSW naming D.J.S, Z.T. and X.W. as inventors. D.J.S. discloses financial interests in ReCode Therapeutics, Signify Bio, Jumble Therapeutics and Tome Biosciences. D.J.S. is a member of the scientific advisory board of ReCode Therapeutics, which has licensed intellectual property from UTSW. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}